RECURRENT GRADE 3B FOLLICULAR LYMPHOMA
Clinical trials for RECURRENT GRADE 3B FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT GRADE 3B FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT GRADE 3B FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to unmask lymphoma cells to the immune system
Disease control OngoingThis phase 2 trial is testing a combination of two drugs, TTI-622 and pembrolizumab, in about 10 adults with diffuse large B-cell lymphoma that has returned or not responded to prior treatment. TTI-622 is a fusion protein that blocks a "don't eat me" signal on cancer cells, while…
Matched conditions: RECURRENT GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 17, 2026 05:47 UTC
-
New combo aims to boost CAR-T power against tough lymphoma
Disease control OngoingThis early-stage trial tests whether adding an experimental drug called NKTR-255 to standard CAR-T cell therapy can improve outcomes for people with large B-cell lymphoma that has returned or not responded to treatment. The study involves about 27 adults and focuses on safety and…
Matched conditions: RECURRENT GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 04, 2026 16:22 UTC